Skip to main content
STARTING YOUR PATIENTS ON KESIMPTA

Life with relapsing MS is complicated, starting treatment shouldn't be

Getting patients started on KESIMPTA®
(ofatumumab)

SCREEN

SCREEN

Bloodwork to screen patients for HBV and test their Ig levels1

Kesimpta sensoready pen icon.

SHOW

Demonstrate KESIMPTA administration using the Sensoready® Demo Pen

Kesimpta start form icon.

START

Start today with samples.* Submit 1-page Start Form

We'll help enroll your patient in Alongside™ KESIMPTA for support and assistance throughout their first year on treatment.
  • HBV and Ig testing can be added to your patient's regular blood panels

  • Training pens and videos are provided by Novartis. We can also provide supplemental virtual one-on-one training for your patient

  • Before initiating KESIMPTA, discuss treatment, including possible side effects like injection reactions, and explain to patients that they start with 1 dose a week for the first 3 weeks, then skip the 4th week before starting once-monthly maintenance dosing

  • Patients can visit KESIMPTA.com for more details, and may also self-enroll in our Alongside program from the patient site

*Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA.

Personalized support for your patients to start and stay on track with treatment

  • Dedicated Alongside KESIMPTA Coordinators tailor support so patients are prepared, not overwhelmed

  • See what else we can help with on the Alongside KESIMPTA page

Patient injection training
Learn how to teach patients to use the Sensoready Pen

Ensure that your patients are getting the coverage and support they need.

 

Call 1-855-537-4678 for assistance or questions about how to help your patients enroll in Alongside KESIMPTA. Support is available 8:30 AM to 8:00 PM ET, Mon-Fri.

“It was great that I could get started on KESIMPTA right away.” – Kristin: mother, real estate agent, KESIMPTA patient.

"It was great that I could get started on KESIMPTA right away."

Kristin: mom, real estate agent, KESIMPTA patient

Real patient taking KESIMPTA who was compensated for time. Individual results may vary.

Support that works with your practice

Everything you need to start patients quickly

clock

Start today with samples

KESIMPTA offers a free trial through its sample program to get patients started today.*

 

Contact a rep for more info

≤ days

Fast start to therapy

80% of eligible patients with commercial insurance start KESIMPTA in 4 days or less through our Bridge Program.2† 

93% coverage

Coverage just got better!

93% of patients enrolled in commercial insurance are covered.

~70% have first-line coverage.3‡

*Sample program is only available to patients who are determined to be appropriate candidates for treatment with KESIMPTA.    
Based on prescription data collected from April to September 2023. 
67% of patients with commercial insurance have first-line coverage. Based on Managed Markets Insight & Technology, LLC database as of May 2024.

Resources to help make KESIMPTA part of your practice

authorizationandappealskit

Download Authorization and Appeals Kit

Download
Preview of patient authorization form

Download Patient Authorization Form

Download
Preview of patient authorization form - Spanish

Download Patient Authorization Form (Spanish)

Download
heta_lb-thumb

Download Jamie-Lynn's KESIMPTA Story Brochure

Download
Laptop showing educational videos

See our educational videos about KESIMPTA and the Sensoready Pen

Visit the KESIMPTA Video Library

Templates to help navigate insurance coverage

sample letter of appeal new to treatment

Download Sample Letter of Appeal - New Treatment

Download
sample letter of appeal change of treatment

Download Sample Letter of Appeal - Change to Treatment

Download
sample letter of medical necessity new to treatment

Download Sample Letter of Medical Necessity - New Treatment

Download
sample letter of medical necessity change of treatment

Download Sample Letter of Medical Necessity - Change of Treatment

Download
Laptop showing educational videos
Visit patient site

Information and resources for treatment with KESIMPTA are available directly to patients. View the KESIMPTA patient site and learn more about these helpful patient services

HBV, hepatitis B virus; Ig, immunoglobulin; MOA, mechanism of action; MS, multiple sclerosis.

IMPORTANT SAFETY INFORMATION

Contraindications: KESIMPTA is contraindicated in patients with active hepatitis B virus (HBV) infection, or history of hypersensitivity to ofatumumab, or life-threatening injection-related reaction to KESIMPTA. Hypersensitivity reactions have included anaphylaxis and angioedema.

Warnings and Precautions

Infections: Serious, including life-threatening or fatal, bacterial, fungal, and new or reactivated viral infections have been observed during and following completion of treatment with anti-CD20 B-cell depleting therapies....

INDICATION

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
CoverMyMeds is a registered trademark of CoverMyMeds, LLC.
References: 1. Kesimpta. Prescribing information. Novartis Pharmaceuticals Corp. 2. Data on file. Program data. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2023. 3. Data on file. Coverage Change-ESI. Novartis Pharmaceuticals Corp; East Hanover, NJ. May 2024.